Alliance Wealth Management Group’s Matinas BioPharma MTNB Stock Holding History

Alliance Wealth Management Group’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-37,734	Closed	-$299K	–	84
2024 Q2	$299K	Buy	+37,734	New	+$342K	0.09%	68
2018 Q2	–	Sell	-8,017	Closed	-$307K	–	67
2018 Q1	$307K	Hold	8,017	–	–	0.14%	57
2017 Q4	$465K	Sell	8,017 -8,016	-50%	-$515K	0.23%	50
2017 Q3	$1.06M	Buy	16,033 +8,016	+100%	+$535K	0.27%	46
2017 Q2	$677K	Hold	8,017	–	–	0.38%	42
2017 Q1	$1.16M	Buy	+8,017	New	+$1.31M	0.67%	33

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Sanctuary Advisors Indianapolis, Indiana $18.5B AUM 23.32% 1-Year Est. Return

Alliance Wealth Management Group's MTNB Position: Q3 2024 in Review

Alliance Wealth Management Group sold out of Matinas BioPharma (MTNB) in Q3 2024, closing a stake of 37,734 shares — an estimated $299K sold.

Alliance Wealth Management Group first reported a position in MTNB in Q1 2017 and held it in 6 quarters. The position peaked at $1.16M in Q1 2017. 18 funds tracked by Wall St. Rank hold MTNB as of Q3 2024.

Alliance Wealth Management Group reported no remaining Matinas BioPharma position as of Q3 2024 after selling out during the quarter.
Alliance Wealth Management Group sold 37,734 Matinas BioPharma shares in Q3 2024, an estimated $299K.
Alliance Wealth Management Group first reported a position in Matinas BioPharma in Q1 2017 and held it in 6 quarters.
Alliance Wealth Management Group's Matinas BioPharma position peaked at $1.16M in Q1 2017.
18 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2024.

Based on Alliance Wealth Management Group's 13F filing for Q3 2024, filed 13 Nov 2024.